The present invention provides a compound having an excellent amount of change in HTP and an excellent HTP saturation rate during exposure, and a liquid crystal composition including the compound. The compound of the present invention is a compound represented by General Formula (A).

(Y).sub.n-G-(X).sub.m   (A)

G represents a group represented by General Formula (B-1) or a group represented by General Formula (B-2), * represents a bonding position, and X and Y represent a predetermined group.

##STR00001##

This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

The present invention relates to monoterpenoid and phenylpropanoid containing derivative compounds, methods of making the compounds, compositions comprising the compounds, and methods of repelling pests using the compounds and/or compositions.

The present invention relates to monoterpenoid and phenylpropanoid containing derivative compounds, methods of making the compounds, compositions comprising the compounds, and methods of repelling pests using the compounds and/or compositions.

Provided is a compound that achieves a good balance between the LO. scavenging ability and the LOO. scavenging ability. The compound of the present invention or a salt thereof is represented by the following formula (1). In the formula (1), R.sup.1 and R.sup.2 may be the same or different and are each independently a hydrogen atom or an alkyl group, R.sup.3 is —OR.sup.4 or —NHR.sup.5, R.sup.4 is a sec-butyl group, a tert-butyl group, or an iso-butyl group, and R.sup.5 is a sec-butyl group, a tert-butyl group, or an iso-butyl group.

Provided is a compound that achieves a good balance between the LO. scavenging ability and the LOO. scavenging ability. The compound of the present invention or a salt thereof is represented by the following formula (1). In the formula (1), R.sup.1 and R.sup.2 may be the same or different and are each independently a hydrogen atom or an alkyl group, R.sup.3 is —OR.sup.4 or —NHR.sup.5, R.sup.4 is a sec-butyl group, a tert-butyl group, or an iso-butyl group, and R.sup.5 is a sec-butyl group, a tert-butyl group, or an iso-butyl group.

The invention relates to bimesogenic compounds of formula I

##STR00001##

to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

The invention relates to bimesogenic compounds of formula I

##STR00001##

to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.